| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
From the Central Drug Research Institute, Lucknow, India.
| Correspondence to: Dr Singh Rajender, Scientist, Division of Endocrinology, Central Drug Research Institute, Lucknow, UP, India (e-mail: rajender_singh{at}cdri.res.in). |
Approximately 50% of infertility issues are attributable to male factors. A
number of different factors may result in similar reductions of sperm count or
motility and affect sperm morphology. Not only is the etiology of male
infertility difficult to understand, but it is equally challenging to treat
male infertility because of its etiological heterogeneity. Because of complex
and incomplete knowledge of the underlying causes, most infertile men are
described as idiopathically oligozoospermic and/or asthenozoospermic.
Different hormonal treatments have been attempted, aiming to improve mainly
endogenous follicle-stimulating hormone and/or androgen levels and subsequent
spermatogenesis. Various studies have tried to treat infertility through
natural pregnancies or increased sperm retrieval for in vitro fertilization
techniques, or by treating spermatozoa in vitro to improve its fertilizing
potential. The present review focuses on all of the aspects of male
infertility treatment by hormone supplementation.
Key words: Spermatogenesis, oligozoospermia, in vitro fertilization
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |